Galp Shares Fall After Q2 EBITDA Miss Despite Profit Beat and Higher Dividend 
Rio Tinto Stock Jumps as Strong Earnings, Higher Dividend and AI Metal Demand Boost Outlook 
BHP, Port Hedland Unions Fail to Reach Wage Deal as Negotiations Continue 
ASML, Applied Materials Slide as China DUV Chip Equipment Breakthrough Sparks Market Jitters 
Philips Shares Slide 10% Despite Earnings Beat as Weak Orders Raise Growth Concerns 
Seagate Stock Jumps as AI-Fueled Earnings Beat and Strong FY2027 Outlook Impress Investors 
Meta CEO Zuckerberg Opposes U.S. Ban on Chinese AI Models, Warns Against Overregulation 
Qualcomm Stock Falls as Weak Q4 Forecast, Apple Revenue Decline Overshadow AI Data Center Growth 
Zabka Shares Drop 10% as Seven & i Abandons Investment Plans 
TeamViewer Shares Fall Despite Profit Growth as ARR and Customer Base Decline 
Zhongji Innolight Raises $6.8 Billion in Hong Kong IPO as AI Demand Fuels Growth 
GSK Unveils $2.52 Billion Cost-Cutting Plan to Accelerate Drug Pipeline 
Serica Energy to Acquire Pharos Energy for £145.7M, Sending PHARP Shares Soaring 
Nvidia Invests $1 Billion in Naver as South Korea AI Data Center Expansion Gains Momentum 
Johnson & Johnson Proposes $5.5 Billion Talc Settlement to Resolve U.S. Ovarian Cancer Lawsuits 
Stellantis Sells Free2move Car-Sharing Business to Mutares to Strengthen Core Auto Strategy 
Exosens H1 Profit Beats Forecasts as Defense Demand Drives Growth 
The enormous rally in Kodak shares is expected to continue after its 318 percent increase on Wednesday on the strength of the Trump administration's announcement that will be transformed into a pharmaceutical producer and would receive a $765 million loan to launch Kodak Pharmaceuticals.
The news propelled the company's shares to a more than 200 percent jump in Tuesday trading that continued on Wednesday with the shares ending with a 318 percent increase.
The stocks climbed over 650 percent at its highest on Wednesday, prompting the New York Stock Exchange to halt trading 20 times.
Kodak, a pre-digital era giant producer of film and cameras, filed for bankruptcy in 2012 and pivoted to turn itself into a materials and chemical company.
It emerged as a restructured business in 2013.
Kodak Pharmaceuticals will produce generic active pharmaceutical ingredients to reduce America's dependency on foreign drug makers.
Kodak CEO Jim Continenza noted that since the company already manufactures essential materials for some pharmaceuticals, the new mission is only expanding that capacity.
He added that it would take around three to three and a half years to establish the new production capacity.
